Polypharmacy in the HIV-infected older adult population

References

• Antiretroviral Therapy Cohort CollaborationLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesLancet2008372963529329918657708
   PubMed Web of Science ®Google Scholar
• EffrosRBFletcherCVGeboKAging and infectious diseases: workshop on HIV infection and aging: what is known and future research directionsClin Infect Dis200847454255318627268
   PubMed Web of Science ®Google Scholar
• ShahSSMcGowanJPSmithCBlumSKleinRSComorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York CityClin Infect Dis200235101238124312410484
   PubMed Web of Science ®Google Scholar
• SimoneMJAppelbaumJHIV in older adultsGeriatrics2008631261219061274
   PubMed Web of Science ®Google Scholar
• GouletJLFultzSLRimlandDAging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?Clin Infect Dis200745121593160118190322
   PubMed Web of Science ®Google Scholar
• GeboKAEpidemiology of HIV and response to antiretroviral therapy in the middle aged and elderlyAging Health20084661562719915688
   PubMedGoogle Scholar
• BushardtRLJonesKWNine key questions to address polypharmacy in the elderlyJAAPA2005185323715918615
   PubMedGoogle Scholar
• HajjarERCaferoACHanlonJTPolypharmacy in elderly patientsAm J Geriatr Pharmacother20075434535118179993
   PubMedGoogle Scholar
• HanlonJTSchmaderKERubyCMWeinbergerMSuboptimal prescribing in older inpatients and outpatientsJ Am Geriatr Soc200149220020911207875
   PubMed Web of Science ®Google Scholar
• BushardtRLMasseyEBSimpsonTWAriailJCSimpsonKNPolypharmacy: misleading, but manageableClin Interv Aging20083238338918686760
   PubMed Web of Science ®Google Scholar
• KaufmanDWKellyJPRosenbergLAndersonTEMitchellAARecent patterns of medication use in the ambulatory adult population of the United States: the Slone surveyJAMA2002287333734411790213
   PubMed Web of Science ®Google Scholar
• FreelandKNThompsonANZhaoYLealJEMauldinPDMoranWPMedication use and associated risk of falling in a geriatric outpatient populationAnn Pharmacother20124691188119222872750
   PubMed Web of Science ®Google Scholar
• ZhanCSanglJBiermanASPotentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel SurveyJAMA2001286222823282911735757
   PubMed Web of Science ®Google Scholar
• FialováDTopinkováEGambassiGAdHOC Project Research GroupPotentially inappropriate medication use among elderly home care patients in EuropeJAMA2005293111348135815769968
   PubMed Web of Science ®Google Scholar
• BuajordetIEbbesenJErikssenJBrørsOHilbergTFatal adverse drug events: the paradox of drug treatmentJ Intern Med2001250432734111576320
   PubMed Web of Science ®Google Scholar
• NolanLO’MalleyKPrescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactionsJ Am Geriatr Soc19883621421493276767
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• LazarouJPomeranzBHCoreyPNIncidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studiesJAMA199827915120012059555760
   PubMed Web of Science ®Google Scholar
• ShorrRIRayWADaughertyJRGriffinMRIncidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureasArch Intern Med199715715168116869250229
   PubMed Web of Science ®Google Scholar
• BjörkmanIKFastbomJSchmidtIKBernstenCBPharmaceutical Care of the Elderly in Europe Research (PEER) GroupDrug–drug interactions in the elderlyAnn Pharmacother200236111675168112398558
   PubMed Web of Science ®Google Scholar
• GurwitzJHFieldTSHarroldLRIncidence and preventability of adverse drug events among older persons in the ambulatory settingJAMA200328991107111612622580
   PubMed Web of Science ®Google Scholar
• FieldTSGurwitzJHHarroldLRRisk factors for adverse drug events among older adults in the ambulatory settingJ Am Geriatr Soc20045281349135415271125
   PubMed Web of Science ®Google Scholar
• JörgensenTJohanssonSKennerfalkAWallanderMASvärdsuddKPrescription drug use, diagnoses, and healthcare utilization among the elderlyAnn Pharmacother20013591004100911573845
   PubMed Web of Science ®Google Scholar
• LeesJChanAPolypharmacy in elderly patients with cancer: clinical implications and managementLancet Oncol201112131249125721741307
   PubMed Web of Science ®Google Scholar
• MaddenJMGravesAJZhangFCost-related medication nonadherence and spending on basic needs following implementation of Medicare Part DJAMA2008299161922192818430911
   PubMed Web of Science ®Google Scholar
• FedermanADAdamsASRoss-DegnanDSoumeraiSBAyanianJZSupplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart diseaseJAMA2001286141732173911594898
   PubMed Web of Science ®Google Scholar
• MillerRRHospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance ProgramArch Intern Med197413422192234843186
   PubMedGoogle Scholar
• RochonPAGurwitzJHOptimising drug treatment for elderly people: the prescribing cascadeBMJ19973157115109610999366745
   PubMed Web of Science ®Google Scholar
• FuAZJiangJZReevesJHPotentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderlyMed Care200745547247617446834
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc201260461663122376048
   PubMed Web of Science ®Google Scholar
• FickDMCooperJWWadeWEWallerJLMacleanJRBeersMHUpdating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of expertsArch Intern Med2003163222716272414662625
   PubMed Web of Science ®Google Scholar
• BeersMHExplicit criteria for determining potentially inappropriate medication use by the elderly. An updateArch Intern Med199715714153115369236554
   PubMed Web of Science ®Google Scholar
• BeersMHOuslanderJGRollingherIReubenDBBrooksJBeckJCExplicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric MedicineArch Intern Med19911519182518321888249
   PubMedGoogle Scholar
• HanlonJTSchmaderKESamsaGPA method for assessing drug therapy appropriatenessJ Clin Epidemiol19924510104510511474400
   PubMed Web of Science ®Google Scholar
• SteinmanMALandefeldCSRosenthalGEBerthenthalDSenSKaboliPJPolypharmacy and prescribing quality in older peopleJ Am Geriatr Soc200654101516152317038068
   PubMed Web of Science ®Google Scholar
• IngersollKSCohenJThe impact of medication regimen factors on adherence to chronic treatment: a review of literatureJ Behav Med200831321322418202907
   PubMed Web of Science ®Google Scholar
• MarzoliniCBackDWeberRSwiss HIV Cohort Study MembersAgeing with HIV: medication use and risk for potential drug–drug interactionsJ Antimicrob Chemother20116692107211121680580
   PubMed Web of Science ®Google Scholar
• MillerCDEl-KholiRFaragonJJLodiseTPPrevalence and risk factors for clinically significant drug interactions with antiretroviral therapyPharmacotherapy200727101379138617896893
   PubMed Web of Science ®Google Scholar
• AmmassariAMurriRPezzottiPAdICONA Study GroupSelf-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infectionJ Acquir Immune Defic Syndr200128544544911744832
   PubMed Web of Science ®Google Scholar
• BarclayTRHinkinCHCastellonSAAge-associated predictors of medication adherence in HIV-positive adults: health beliefs, self- efficacy, and neurocognitive statusHealth Psychol2007261404917209696
   PubMed Web of Science ®Google Scholar
• HinkinCHHardyDJMasonKIMedication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuseAIDS200418Suppl 1S19S2515075494
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med20001331213010877736
   PubMed Web of Science ®Google Scholar
• LiedtkeMDRathbunRCWarfarin-antiretroviral interactionsAnn Pharmacother200943232232819196837
   PubMed Web of Science ®Google Scholar
• de MaatMMEkhartGCHuitemaADKoksCHMulderJWBeijnenJHDrug interactions between antiretroviral drugs and comedicated agentsClin Pharmacokinet200342322328212603174
   PubMed Web of Science ®Google Scholar
• FellayJMarzoliniCDecosterdLVariations of CYP3 A activity induced by antiretroviral treatment in HIV-1 infected patientsEur J Clin Pharmacol2005601286587315657782
   PubMed Web of Science ®Google Scholar
• EaglingVABackDJBarryMGDifferential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavirBr J Clin Pharmacol19974421901949278209
   PubMed Web of Science ®Google Scholar
• RheeMSGreenblattDJPharmacologic consideration for the use of antiretroviral agents in the elderlyJ Clin Pharmacol200848101212122518812611
   PubMed Web of Science ®Google Scholar
• NachegaJBHsuAJUthmanOASpinewineAPhamPAAntiretroviral therapy adherence and drug–drug interactions in the aging HIV populationAIDS201226Suppl 1S39S5322781176
   PubMedGoogle Scholar
• KlotzUPharmacokinetics and drug metabolism in the elderlyDrug Metab Rev2009412677619514965
   PubMed Web of Science ®Google Scholar
• SitarDSAging issues in drug disposition and efficacyProc West Pharmacol Soc200750162018605223
   PubMedGoogle Scholar
• MarchesiniGBuaVBrunoriAGalactose elimination capacity and liver volume in aging manHepatology198885107910833417228
   PubMed Web of Science ®Google Scholar
• WynneHACopeLHMutchERawlinsMDWoodhouseKWJamesOFThe effect of age upon liver volume and apparent liver blood flow in healthy manHepatology1989922973012643548
   PubMed Web of Science ®Google Scholar
• ManfrediRHIV infection and advanced age emerging epidemiological, clinical, and management issuesAgeing Res Rev200431315415164725
   PubMed Web of Science ®Google Scholar
• SulkowskiMSDrug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitorsClin Infect Dis200438Suppl 2S90S9714986280
   PubMed Web of Science ®Google Scholar
• ClarkWFSontropJMMacnabJJUrine volume and change in estimated GFR in a community-based cohort studyClin J Am Soc Nephrol20116112634264121885793
   PubMed Web of Science ®Google Scholar
• GuptaSKEustaceJAWinstonJAGuidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of AmericaClin Inf Dis2005401115591585
   PubMed Web of Science ®Google Scholar
• ChoiAIRodriguezRABacchettiPBertenthalDVolberdingPAO’HareAMRacial differences in end-stage renal disease rates in HIV infection versus diabetesJ Am Soc Nephrol200718112968297417942954
   PubMed Web of Science ®Google Scholar
• MocroftAKirkOGatellJChronic renal failure among HIV-1-infected patientsAIDS20072191119112717502722
   PubMed Web of Science ®Google Scholar
• ScherzerREstrellaMLiYAssociation of tenofovir exposure with kidney disease risk in HIV infectionAIDS201226786787522313955
   PubMed Web of Science ®Google Scholar
• KalayjianRCFranceschiniNGuptaSKSuppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney diseaseAIDS200822448148718301060
   PubMed Web of Science ®Google Scholar
• CohenCElionRRuanePRandomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionAIDS2011256F7F1221412057
   PubMed Web of Science ®Google Scholar
• ElionRCohenCGatheJGS-US-216-0105 Study TeamPhase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionAIDS201125151881188621811136
   PubMed Web of Science ®Google Scholar
• WormSWSabinCWeberRRisk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) studyJ Infect Dis2010201331833020039804
   PubMed Web of Science ®Google Scholar
• SeabergECMuñozALuMMulticenter AIDS Cohort StudyAssociation between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003AIDS200519995396015905677
   PubMed Web of Science ®Google Scholar
• SattlerFRQianDLouieSElevated blood pressure in subjects with lipodystrophyAIDS200115152001201011600829
   PubMed Web of Science ®Google Scholar
• HadiganCMeigsJBCorcoranCMetabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophyClin Infect Dis200132113013911118392
   PubMed Web of Science ®Google Scholar
• GlesbyMJAbergJAKendallMAet al; for Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersClin Pharmacol Ther200578214315316084849
   PubMed Web of Science ®Google Scholar
• AIDSinfoGuidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents [webpage on the Internet]Rockville, MDDepartment of Health and Human Services2013 Available from: http://aidsinfo.nih.gov/guidelinesAccessed 27 Feb, 2013
   Google Scholar
• ChengJWRybakIUse of digoxin for heart failure and atrial fibrillation in elderly patientsAm J Geriatr Pharmacother20108541942721335295
   PubMedGoogle Scholar
• KoupJRGreenblattDJJuskoWJSmithTWKoch-WeserJPharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion dosesJ Pharmacokinet Biopharm1975331811921159622
   PubMedGoogle Scholar
• SchmittCKaeserBRiekMBechNKreuzerCEffect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probeInt J Clin Pharmacol Ther201048319219920197013
   PubMed Web of Science ®Google Scholar
• KnoellKRYoungTMCousinsESPotential interaction involving warfarin and ritonavirAnn Pharmacother19983212129913029876810
   PubMed Web of Science ®Google Scholar
• KaminDSGrinspoonSKCardiovascular disease in HIV-positive patientsAIDS200519764165215821390
   PubMed Web of Science ®Google Scholar
• DubéMPCaddenJJLipid metabolism in treated HIV InfectionBest Prac Res Clin Endocrinol Metab2011253429442
   PubMed Web of Science ®Google Scholar
• DubéMPSteinJHAbergJAAdult AIDS Clinical Trials Group Cardiovascular SubcommitteeHIV Medical Association of the Infectious Diseases Society of AmericaGuidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupClin Infect Dis200337561362712942391
   PubMed Web of Science ®Google Scholar
• SamineniDDesaiPBSallansLFichtenbaumCJSteady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatinJ Clin Pharm2012526922931
   PubMed Web of Science ®Google Scholar
• AquilanteCLKiserJJAndersonPLInfluence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatinJ Clin Pharm2012521117251738
   Web of Science ®Google Scholar
• GerberJGRosenkranzSLFichtenbaumCJet al; for AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJ Acquir Immune Defic Syndr200539330731215980690
   PubMed Web of Science ®Google Scholar
• GarrawayWMCollinsGNLeeRJHigh prevalence of benign prostatic hypertrophy in the communityLancet199133887654694711714529
   PubMed Web of Science ®Google Scholar
• BerrySJCoffeyDSWalshPCEwingLLThe development of human benign prostatic hyperplasia with ageJ Urol198413234744796206240
   PubMed Web of Science ®Google Scholar
• KirbyRSThe natural history of benign prostatic hyperplasia: what have we learned in the last decade?Urology2000565 Suppl 13611074195
   PubMed Web of Science ®Google Scholar
• Franco-SalinasGde la RosetteJJMichelMCPharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulationsClinical Pharmacokinet2010493177188
   PubMed Web of Science ®Google Scholar
• LallemandFSalhiYLinardFGiamiARozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitorsJ Acquir Immune Defic Syndr200230218719012045681
   PubMed Web of Science ®Google Scholar
• CoronaGRazzoliEFortiGMaggiMThe use of phosphodiesterase 5 inhibitors with concomitant medicationsJ Endocrinol Invest200831979980818997493
   PubMed Web of Science ®Google Scholar
• GurSKadowitzPJGokceASikkaSCLokmanUHellstromWJUpdate on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertensionCurr Drug Metab201314226526923140258
   PubMed Web of Science ®Google Scholar
• NkuizeMDe WitSMulsVArvanitakisMBusetMUpper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapyHIV Med201011641241720146733
   PubMed Web of Science ®Google Scholar
• WangXBoffitoMZhangJEffects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patientsAIDS Patient Care STDS201125950951521770762
   PubMed Web of Science ®Google Scholar
• LuberADBrowerRKimDSilvermanRPeloquinCAFrankISteady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteersHIV Med20078745746417760738
   PubMed Web of Science ®Google Scholar
• WinstonABackDFletcherCEffect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteersAIDS200620101401140616791014
   PubMed Web of Science ®Google Scholar
• LynessJMCaineEDKingDACoxCYoedionoZPsychiatric disorders in older primary care patientsJ Gen Intern Med199914424925410203638
   PubMed Web of Science ®Google Scholar
• CieslaJARobertsJEMeta-analysis of the relationship between HIV infection and risk for depressive disordersAm J Psychiatry2001158572573011329393
   PubMed Web of Science ®Google Scholar
• CaballeroJNahataMCUse of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIVAnn Pharmacother200539114114515562140
   PubMed Web of Science ®Google Scholar
• ElliottAJUldallKKBergamKRussoJClaypooleKRoy-ByrnePPRandomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatientsAm J Psychiatry199815533673729501747
   PubMed Web of Science ®Google Scholar
• van der LeeMJBlenkeAARongenGAInteraction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjectsAntimicrob Agents Chemother200751114098410417846135
   PubMed Web of Science ®Google Scholar
• GreenblattDJvon MoltkeLLHarmatzJSShort-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodoneJ Clin Pharmacol200343441442212723462
   PubMed Web of Science ®Google Scholar
• HogelandGWSwindellsSMcNabbJCKashubaADYeeGCLindleyCMLopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjectsClin Pharmacol Ther2007811697517186001
   PubMed Web of Science ®Google Scholar
• MerryCMulcahyFBarryMGibbonsSBackDSaquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV diseaseAIDS19971122682699030388
   PubMed Web of Science ®Google Scholar
• SchmittCHofmannCRiekMPatelAZwanzigerEEffect of saquinavir-ritonavir on cytochrome P450 3 A4 activity in healthy volunteers using midazolam as a probePharmacotherapy200929101175118119792991
   PubMed Web of Science ®Google Scholar
• BrackettCCSevere prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy: a commentaryPharmacotherapy2013335e85e8623065869
   PubMed Web of Science ®Google Scholar
• GreenblattDJvon MoltkeLLDailyJPHarmatzJSShaderRIExtensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and inductionJ Clin Psychopharmacol199919429329610440454
   PubMed Web of Science ®Google Scholar
• OwensRCJrQT prolongation with antimicrobial agents: understanding the significanceDrugs200464101091112415139788
   PubMed Web of Science ®Google Scholar
• OwensRCJrNolinTDAntimicrobial-associated QT interval prolongation: pointes of interestClin Infect Dis200643121603161117109296
   PubMed Web of Science ®Google Scholar
• BaciewiczAMChrismanCRFinchCKSelfTHUpdate on rifampin, rifabutin, and rifapentine drug interactionsCurr Med Res Opin201329111223136913
   PubMed Web of Science ®Google Scholar
• De PontiFPoluzziECavalliARecanatiniMMontanaroNSafety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overviewDrug Saf200225426328611994029
   PubMed Web of Science ®Google Scholar
• KrishnaGMotonAMaLMartinhoMSeiberlingMMcLeodJEffects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteersJ Acquir Immune Defic Syndr200951443744419623694
   PubMed Web of Science ®Google Scholar
• YoganathanKDavidLWilliamsCJonesKCushing’s syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infectionIntl J STD AIDS2012237520521
   PubMed Web of Science ®Google Scholar
• FrankelJKPackerCDCushing’s syndrome due to antiretroviral-budesonide interactionAnn Pharmacother201145682382421558486
   PubMed Web of Science ®Google Scholar
• PenzakSRFormentiniEAlfaroRMLongMNatarajanVKovacsJPrednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteersJ Acquir Immune Defic Syndr200540557358016284534
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIOxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavirEur J Clin Pharmacol2010661097798520697700
   PubMed Web of Science ®Google Scholar
• ClarkeSMulcahyFBerginCAbsence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavirClin Infect Dis20023481143114511915005
   PubMed Web of Science ®Google Scholar
• BartPARizzardiPGGallantSMethadone blood concentrations are decreased by the administration of abacavir plus amprenavirTher Drug Monit200123555355511591903
   PubMed Web of Science ®Google Scholar
• SekarVTomakaFLefebvreEPharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxoneJ Clin Pharmacol201151227127820421512
   PubMed Web of Science ®Google Scholar
• JamoisCSmithPMorrisonREffect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapyAddict Biol200914332132719523046
   PubMed Web of Science ®Google Scholar
• BrownTTQaqishRBAntiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewAIDS200620172165217417086056
   PubMed Web of Science ®Google Scholar
• Walker HarrisVBrownTTBone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategiesJ Infect Dis2012205Suppl 3S391S39822577213
   PubMed Web of Science ®Google Scholar
• TortiCMazziottiGSoldiniPAHigh prevalence of radiological vertebral fractures in HIV-infected malesEndocrine201241351251722198528
   PubMed Web of Science ®Google Scholar
• YoungBDaoCNBuchaczKBakerRBrooksJTHIV Outpatient Study (HOPS) InvestigatorsIncreased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006Clin Infect Dis20115281061106821398272
   PubMed Web of Science ®Google Scholar
• BollandMJGreyABHorneAMAnnual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trialJ Clin Endocrinol Metab20079241283128817227801
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Lanoy E, Bentata M, et al; for ANRS 120 Fosivir Study Group. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)AIDS Res Hum Retroviruses201228997298022353022
   PubMed Web of Science ®Google Scholar
• BeersMHDangJHasegawaJTamaiIYInfluence of hospitalization on drug therapy in the elderlyJ Am Geriatr Soc19893786796832754151
   PubMed Web of Science ®Google Scholar
• BedellSEJabbourSGoldbergRDiscrepancies in the use of medications: their extent and predictors in an outpatient practiceArch Intern Med2000160142129213410904455
   PubMed Web of Science ®Google Scholar
• WilsonIBSchoenCNeumanPPhysician-patient communication about prescription medication nonadherence: a 50-state study of America’s seniorsJ Gen Intern Med200722161217351835
   PubMed Web of Science ®Google Scholar
• BayoumiIHowardMHolbrookAMSchabortIInterventions to improve medication reconciliation in primary careAnn Pharmacother200943101667167519737997
   PubMed Web of Science ®Google Scholar
• SteinmanMAHanlonJTManaging medications in clinically complex elders: “There’s got to be a happy medium”JAMA2010304141592160120940385
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Eng J Med20053535487497
   PubMed Web of Science ®Google Scholar
• BoydCMDarerJBoultCFriedLPBoultLWuAWClinical practice guidelines and quality of care for older patients with multiple comorbid disease: implications for pay for performanceJAMA2005294671672416091574
   PubMed Web of Science ®Google Scholar
• RochonPAStukelTASykoraKAtypical antipsychotics and parkinsonismArch Int Med2005165161882188816157833
   PubMed Web of Science ®Google Scholar
• ClarkeNKabadiUMOptimizing treatment of hypothyroidismTreat Endocrinol20043421722116026104
   PubMedGoogle Scholar
• WolfMSShekellePChoudhryNKAgnew-BlaisJParkerRMShrankWHVariability in pharmacy interpretations of physician prescriptionsMed Care200947337037319194338
   PubMed Web of Science ®Google Scholar
• WolfMSCurtisLMWaiteKHelping patients simplify and safely use complex prescription regimensArch Intern Med2011171430030521357804
   PubMed Web of Science ®Google Scholar
• Work Group forHIVAging Consensus PanelSummary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virusJ Am Geriatr Soc201260597497922568508
   PubMed Web of Science ®Google Scholar
• HanlonJTWeinbergerMSamsaGPA randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacyAm J Med199610044284378610730
   PubMed Web of Science ®Google Scholar
• VinksTHEgbertsTCde LangeTMde KoningFHPharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trialDrugs Aging200926212313319220069
   PubMed Web of Science ®Google Scholar
• WatersLPattersonBScourfieldAA dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experienceInt J STD AIDS201223854655222930290
   PubMed Web of Science ®Google Scholar
• Edmunds-OgbuokiriJClinically significant drug interactions in the HIV-infected elderlyHIV Clin20112321215
   Google Scholar